Parametric Portfolio Associates’s UroGen Pharma URGN Stock Holding History

Parametric Portfolio Associates’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$622K	Buy	71,392 +51,480	+259%	+$401K	﹤0.01%	2994
2021 Q4	$189K	Sell	19,912 -51,133	-72%	-$721K	﹤0.01%	3437
2021 Q3	$1.2M	Buy	71,045 +5,866	+9%	+$93K	﹤0.01%	2719
2021 Q2	$995K	Buy	65,179 +50,489	+344%	+$913K	﹤0.01%	2777
2021 Q1	$286K	Sell	14,690 -14,129	-49%	-$300K	﹤0.01%	3736
2020 Q4	$519K	Buy	28,819 +396	+1%	+$8.3K	﹤0.01%	3366
2020 Q3	$548K	Buy	28,423 +3,095	+12%	+$70.1K	﹤0.01%	3226
2020 Q2	$662K	Buy	25,328 +579	+2%	+$14.2K	﹤0.01%	3127
2020 Q1	$442K	Buy	24,749 +3,792	+18%	+$102K	﹤0.01%	3231
2019 Q4	$699K	Buy	20,957 +1,237	+6%	+$33.8K	﹤0.01%	3235
2019 Q3	$470K	Buy	19,720 +13,627	+224%	+$446K	﹤0.01%	3372
2019 Q2	$219K	Buy	+6,093	New	+$225K	﹤0.01%	3707

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Parametric Portfolio Associates's URGN Position: Q1 2022 in Review

Parametric Portfolio Associates increased its UroGen Pharma (URGN) stake by 259% in Q1 2022, buying an estimated $401K and bringing the position to 71,392 shares worth $622K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Parametric Portfolio Associates first reported a position in URGN in Q2 2019 and has held it in 12 quarters since. The position peaked at $1.2M in Q3 2021. 83 funds tracked by Wall St. Rank hold URGN as of Q1 2022.

Parametric Portfolio Associates held 71,392 shares of UroGen Pharma worth $622K as of Q1 2022.
Parametric Portfolio Associates bought 51,480 UroGen Pharma shares in Q1 2022, an estimated $401K.
UroGen Pharma made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2994 holding.
Parametric Portfolio Associates first reported a position in UroGen Pharma in Q2 2019 and has held it in 12 quarters since.
Parametric Portfolio Associates's UroGen Pharma position peaked at $1.2M in Q3 2021.
83 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.